Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Other Accumulated Expenses (2016 - 2023)

Vistagen Therapeutics (VTGN) has disclosed Other Accumulated Expenses for 8 consecutive years, with $10000.0 as the latest value for Q2 2023.

  • Quarterly Other Accumulated Expenses rose 85.19% to $10000.0 in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $10000.0 through Jun 2023, up 85.19% year-over-year, with the annual reading at $32700.0 for FY2022, 17.63% up from the prior year.
  • Other Accumulated Expenses hit $10000.0 in Q2 2023 for Vistagen Therapeutics, up from $1200.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $62600.0 in Q3 2021 to a low of $1200.0 in Q3 2022.
  • Historically, Other Accumulated Expenses has averaged $17523.1 across 5 years, with a median of $10000.0 in 2023.
  • Biggest five-year swings in Other Accumulated Expenses: surged 281.71% in 2021 and later tumbled 98.08% in 2022.
  • Year by year, Other Accumulated Expenses stood at $7900.0 in 2019, then crashed by 30.38% to $5500.0 in 2020, then surged by 1038.18% to $62600.0 in 2021, then crashed by 98.08% to $1200.0 in 2022, then skyrocketed by 733.33% to $10000.0 in 2023.
  • Business Quant data shows Other Accumulated Expenses for VTGN at $10000.0 in Q2 2023, $1200.0 in Q3 2022, and $5400.0 in Q2 2022.